According to the April 22nd edition of the Wall Street Journal, GlaxoSmithKline will acquire Sirtris Pharmaceuticals, a Massachusetts company that’s developing a drug based on resveratrol, a chemical found in red wine that is thought to fight some effects of aging.

Glaxo said in a news release that the $720 million deal will help it get involved with sirtuins, a recently-discovered class of enzymes believed to have a role in the aging process. The WSJ article went on to say that Sirtris’ red-wine drug, which targets the sirtuin 1 enzyme, was well-tolerated and safe for patients in an early study in diabetics.

It’s still early to tell whether the drug, code named SRT501, will work out. In the meantime, WSJ claims Sirtris has also been working on some new compounds that it says mimic the effects of resveratrol but with much more potency. Glaxo said targeting the sirtuin family could help it address diseases associated with metabolism and aging such as diabetes, muscle wasting and neurodegeneration.